Místo a důležitost kyseliny hyaluronové při nežádoucích účincích radioterapie

Stiahnuť PDF English version

Autori: Y. B. Cihan
Pôsobisko autorov: Department of Radiation Oncology, Kayseri City Hospital, Kayseri, Turkey
Vyšlo v časopise: Klin Onkol 2021; 34(5): 346-349
Kategória: Reviews
doi: https://doi.org/10.48095/ccko2021346

Súhrn

Východiska: Kyselina hyaluronová (HA) je jednou z největších a nejdůležitějších složek extracelulární matrix. Ve větším množství se nachází ve vitreální tekutině, pupeční šňůře, dermis, synoviální tekutině a srdečních chlopních. Až 80–90 % cirkulující HA podléhá katabolizmu v játrech a 10 % je vylučováno ledvinami. Používá se v mnoha oborech medicíny. Studie prokázaly, že má angiogenní a antiadhezivní účinek, působí při ukládání kolagenu, mezibuněčných interakcích a interakcích buněk s buněčnou matrix, vyrovnání osmotického tlaku, odstraňování buněčného odpadu, vyrovnává distribuci proteinů o vysoké molekulové hmotnosti, má zánětlivý účinek, zvyšuje angiogenezi, hojení ran a má imunostimulační účinek. Kromě těchto základních vlastností má řadu dalších funkcí podle typu tkáně, ve které se nachází, a typu buněk, ze kterých je secernována. Dosud nebyly hlášeny nežádoucí účinky ani interakce s léčivy. Podle literatury se HA jeví jako účinná a bezpečná volba při léčbě akutních i chronických nežádoucích účinků, které se vyskytují nebo vyskytnou během radioterapie. Jsou ale třeba další studie zaměřené na to, jakým způsobem a jak často se může HA používat. Cíl: V tomto přehledném článku jsou ve světle literatury diskutována data týkající se účinnosti HA při snižování akutních a chronických nežádoucích účinků vyvolaných radioterapií.

Klíčová slova:

radioterapie – nežádoucí účinky – kyselina hyaluronová

Zdroje

1. Ahmadian E, Dizaj SM, Eftekhari A et al. The potential applications of hyaluronic acid hydrogels in biomedicine. Drug Res (Stuttg). 2020; 70 (1): 6–11. doi: 10.1055/a-0991-7585.

2. Zhu J, Tang X, Jia Y et al. Applications and delivery mechanisms of hyaluronic acid used for topical/transdermal delivery – a review. Int J Pharm 2020; 578: 119127. doi: 10.1016/j.ijpharm.2020.119127.

3. Walker K, Basehore BM, Goyal A et al. Hyaluronic acid. Treasure Island (FL): StatPearls Publishing 2020.

4. Kim JH, Moon MJ, Kim DY et al. Hyaluronic acid-based nanomaterials for cancer therapy. Polymers (Basel) 2018; 10 (10): 1133. doi: 10.3390/polym10101133.

5. Huynh A, Priefer R. Hyaluronic acid applications in ophthalmology, rheumatology, and dermatology. Carbohydr Res 2020; 489: 107950. doi: 10.1016/j.carres.2020.107 950.

6. Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004; 83 (7): 317–325. doi: 10.1078/0171-9335-00392.

7. Brown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 2005; 19 (3): 308–318. doi: 10.1111/j.1468-3083.2004.01180.x.

8. Necas J, Bartosikova, Brauner P et al. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina 2008; 53 (8): 397–411.

9. Abatangelo G, Vindigni V, Avruscio G et al. Hyaluronic acid: redefining its role. Cells 2020; 9 (7): 1743. doi: 10.3390/cells9071743.

10. Lloyd L, Kennedy JF, Methacanon M et al. Carbohydrate polymers as wound management aids. Carbohydrate Polymers 1998; 37 (3): 315–322.

11. Hiro D, Ito A, Matsuta K et al. Hyaluronic acid is an endogenous inducer of interleukin-1 production by human monocytes and rabbit macrophages. Biochem Biophys Res Commun 1986; 140 (2): 715–722. doi: 10.1016/0006-291x (86) 90790-4.

12. Vigetti D, Karousou E, Viola M et al. Hyaluronan: biosynthesis and signaling. Biochim Biophys Acta 2014; 2 (1): 2452–2459. doi: 10.1016/j.bbagen.2014.02.001.

13. Goldberg RL, Toole BP. Hyaluronate inhibition of cell proliferation. Arthritis Rheum 1987; 30 (7): 769–778. doi: 10.1002/art.1780300707.

14. Ariyoshi W, Okinaga T, Knudson W et al. High molecular weight hyaluronic acid regulates osteoclast formation by inhibiting receptor activator of NF-kB ligand through Rho kinase. Osteoarthritis Cartilage 2014; 22 (1): 111–120. doi: 10.1016/j.joca.2013.10.013.

15. Lovvorn HN, Cass DL, Sylvester KG et al. Hyaluronan receptor expression increases in fetal excisional skin wounds and correlates with fibroplasia. J Pediatr Surg 1998; 33 (7): 1062–1069. doi: 10.1016/s0022-3468 (98) 90532-2.

16. Dam-Hieu P, Lacroix C, Said G et al. Reduction of postoperative perineural adhesions by Hyaloglide gel: an experimental study in the rat sciatic nerve. Neurosurgery 2005; 56 (2 Suppl): 425–433; doi: 10.1227/01.neu.0000156845.41626.e9.

17. Ikeda K, Yamauchi D, Osamura N et al. Hyaluronic acid prevents peripheral nerve adhesion. Br J Plast Surg 2003; 56 (4): 342–347. doi: 10.1016/s0007-1226 (03) 00 197-8.

18. Dinicola S, Pasta V, Costantino D et al. Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy. Minerva Ginecol 2015; 67 (6): 523–531.

19. Cosentino D, Piro F. Hyaluronic acid for treatment of the radiation therapy side effects: a systematic review. Eur Rev Med Pharmacol Sci 2018; 22 (21): 7562–7572. doi: 10.26355/eurrev_201811_16298.

20. Presta G, Puliatti A, Bonetti L et al. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapyassociated with cetuximab: a case report and review. Int Wound J 2019; 16 (6): 1433–1439. doi: 10.1111/iwj.13210.

21. Shao Y, Lu GL, Shen ZJ.Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis. BJU Int 2012; 109 (5): 691–694. doi: 10.1111/j.1464-410X.2011.10550.x.

22. Delia P, Sansotta G, Pontoriero A et al. Clinical evaluation of low-molecular-weight hyaluronic acid-based treatment on onset of acute side effects in women receiving adjuvant radiotherapy after cervical surgery: a randomized clinical trial. Oncol Res Treat 2019; 42 (4): 217–223. doi: 10.1159/000496036.

23. Struik GM, Godart J, Verduijn GM et al. A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol. Trials 2018; 19 (1): 689. doi: 10.1186/s13063-018-3035-3.

24. Primavera G, Carrera M, Berardesca E et al. A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis. Cutan Ocul Toxicol 2006; 25 (3): 165–171. doi: 10.1080/15569520600860009.

25. Pardo Masferrer J, Murcia Mejía M, Vidal Fernández M et al. Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis. Clin Transl Oncol 2010; 12 (1): 43–48. doi: 10.1007/s12094-010-0465-0.

26. Pinnix C, Perkins GH, Strom EA et al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys 2012; 83 (4): 1089–1094. doi: 10.1016/j.ijrobp.2011.09.021.

27. Gacci M, Saleh O, Giannessi C et al. Bladder instillation therapy with hyaluronic acid and chondroitin sulfate improves symptoms of postradiation cystitis: prospective pilot study. Clin Genitourin Cancer 2016; 14 (5): 444–449. doi: 10.1016/j.clgc.2016.01.016.

28. Boissier R, Udrescu C, Rebillard X et al.Technique of injection of hyaluronic acid as a prostatic spacer and fiducials before hypofractionated external beam radiotherapy for prostate cancer. Urology 2017; 99: 265–269. doi: 10.1016/j.urology.2016.09.045.

29. Chapet O, Decullier E, Bin S et al. Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study. Int J Radiat Oncol Biol Phys 2015; 91 (4): 730–736. doi: 10.1016/j.ijrobp.2014.11.027.

30. Prada PJ, Fernández J, Martinez AA et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007; 69 (1): 95–102. doi: 10.1016/j.ijrobp.2007.02.034.

31. Chapet O, Udrescu C, Tanguy R et al. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014; 88 (2): 425–432. doi: 10.1016/j.ijrobp.2013.10.039.

32. Wilder RB, Barme GA, Gilbert RF et al. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 2011; 10 (1): 44–50. doi: 10.1016/j.brachy.2009.12.005.

33. Prada PJ, Gonzalez H, Menéndez C et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009; 8 (2): 210–217. doi: 10.1016/j.brachy.2008.11.010.

34. Prada PJ, Jimenez I, González-Suárez H et al. High--dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012; 11 (2): 105–110. doi: 10.1016/j.brachy.2011.05.003.

35. Peckinpaugh JL, Reddy HS, Tower RN. Large particle hyaluronic acid gel for the treatment of lower eyelid retraction associated with radiation-induced lipoatrophy. Ophthalmic Plast Reconstr Surg 2010; 26 (5): 377–379. doi: 10.1097/IOP.0b013e3181cc85b0.

36. Wu WJ, Gao Y, Liu SM et al. Subcutaneous injection of hyaluronic acid to decrease acute skin toxicity after adjuvant interstitial brachytherapy in parotid gland cancer patients: a nonrandomized controlled trial. J Oral Maxillofac Surg 2020; 78 (1): 167–172. doi: 10.1016/j.joms.2019.09.005.

37. Barber C, Powell R, Ellis A et al. Comparing pain control and ability to eat and drink with standard therapy vs Gelclair: a preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis. Support Care Cancer 2007; 15 (4): 427–440. doi: 10.1007/s00520-006-0171-1.

38. Murakami N, Shima S, Kashihara T et al. Hyaluronic gel injection into the vesicovaginal septum for high-dose-rate brachytherapy of uterine cervical cancer: an effective approach for bladder dose reduction. J Contemp Brachytherapy 2019; 11 (1): 1–7. doi: 10.5114/jcb.2019.82612.

39. Liguori V, Guillemin C, Pesce GF et al. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiother Oncol 1997; 42 (2): 155–161. doi: 10.1016/s0167-8140 (96) 01882-8.